Lead Product(s) : Anagliptin
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus
Details : Anagliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 23, 2021
Lead Product(s) : Anagliptin
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable